A 69-year-old man with diabetes and ASCVD has an A1C of 7.4% on metformin and empagliflozin. He seeks further cardiovascular benefit with weight loss....

Question

A 69-year-old man with diabetes and ASCVD has an A1C of 7.4% on metformin and empagliflozin. He seeks further cardiovascular benefit with weight loss. What is the best add-on therapy?

Accepted Answer

GLP-1 receptor agonist with cardiovascular benefit

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

Basal insulin

Answer

Pioglitazone

us-abfm MCQ (SBA): Type 2 Diabetes CV Risk

A 69-year-old man with diabetes and ASCVD has an A1C of 7.4% on metformin and empagliflozin. He seeks further cardiovascular benefit with weight loss. What is the best add-on therapy?